Fast Shipping
Volume Discounts
Dedicated Support
≥99% Purity
GLP-1sg (Semaglutide)
AUTHENTICHAIN
View COA's →

This product has been independently tested by a licensed, accredited laboratory and has passed all quality and purity standards.

ProductGLP-1sg (Semaglutide)
Latest LotSIG-2026-0312
TestedMar 10, 2026
ResultPassed — ≥99%
Verified ByNFC + Blockchain
● In Stock

GLP-1sg (Semaglutide)

20mg
FormLyophilized Powder
Vial Size3ml
Purity99%
ManufacturerUSA

Volume Pricing

Per unit — bulk discounts applied automatically
1–9vials
$131.25
10–24vials
$118.25Save 10%
25–49vials
$105.00Save 20%
50+vials
$93.75Save 29%
Order by 12PM EST for same-day shipping
Apply for Access to Order →

Wholesale pricing available for approved accounts

About GLP-1sg (Semaglutide)

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. This 20mg lyophilized formulation is designed for advanced research protocols. Semaglutide is extensively studied for its role in glycemic regulation, appetite modulation, and metabolic pathway research, with demonstrated effects on pancreatic beta-cell function, gastric motility, and central nervous system satiety signaling.

Frequently Asked Questions

All Signal peptides undergo rigorous third-party testing and are guaranteed ≥99% purity. Every batch comes with a Certificate of Analysis (COA) verified through AuthentiChain's blockchain verification system.

Orders placed before 12PM EST ship same-day via cold chain logistics. Products are shipped in insulated packaging with dry ice to maintain temperature integrity. Standard delivery is 1–3 business days.

Approved accounts have access to flexible payment terms including NET 30, wire transfer, and credit card. Volume-based pricing is automatically applied at checkout based on your order quantity.

Absolutely. Contact your dedicated account manager or reach out to info@signalpeps.com with the product name and lot number. COAs are also available digitally through our AuthentiChain verification badge on each product page.

Backed by Research

Published Study Findings on GLP-1sg (Semaglutide)

Detailed Research & Citations

In-depth findings from peer-reviewed preclinical and clinical studies

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. Modified with a C-18 fatty di-acid chain and an amino acid substitution at position 8 to resist DPP-4 degradation, Semaglutide exhibits an extended half-life of approximately 7 days. It is extensively studied for its role in glycemic regulation, appetite modulation, and metabolic pathway research.

Glycemic Regulation

Superior HbA1c Reduction

In the SUSTAIN clinical trial program, semaglutide demonstrated superior HbA1c reductions of 1.5–1.8% compared to placebo and active comparators including sitagliptin, exenatide ER, and insulin glargine across diverse type 2 diabetes populations.

Life Sciences (2022)
Weight Management

Significant Body Weight Reduction

The STEP 1 trial demonstrated that semaglutide 2.4mg weekly produced a mean body weight reduction of 14.9% (vs 2.4% placebo) over 68 weeks in adults with overweight or obesity, with 86.4% of participants achieving ≥5% weight loss.

New England Journal of Medicine (2021)
Cardiovascular

Cardiovascular Risk Reduction

SUSTAIN-6 demonstrated a 26% reduction in major adverse cardiovascular events (MACE) — cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke — in patients with type 2 diabetes at high cardiovascular risk treated with semaglutide.

New England Journal of Medicine (2016)
Appetite Regulation

Central Appetite Modulation

Semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in hypothalamic appetite centers, reducing hunger, increasing satiety, and decreasing food cravings. Neuroimaging studies showed reduced neural responses to food cues in reward-related brain areas.

New England Journal of Medicine (2021)
Metabolic

Beta-Cell Function Preservation

Semaglutide demonstrated glucose-dependent insulin secretion stimulation and glucagon suppression, improving beta-cell function indices (HOMA-B) and preserving pancreatic beta-cell mass in preclinical models.

Life Sciences (2022)
Pharmacokinetics

Extended Half-Life & Stability

The C-18 fatty di-acid side chain enables strong albumin binding, and the Aib8 substitution confers DPP-4 resistance, yielding a plasma half-life of ~168 hours (7 days) — supporting once-weekly dosing with sustained receptor activation.

Life Sciences (2022)
View All 3 Sources
  1. Semaglutide, a glucagon-like peptide-1 receptor agonist with cardiovascular benefits — A comprehensive reviewMahapatra MK, Karuppasamy M, Sahoo BMLife Sciences (2022)PMID: 35472436
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)Wilding JPH, Batterham RL, Calanna S, et al.New England Journal of Medicine (2021)PMID: 33567185
  3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)Marso SP, Bain SC, Consoli A, et al.New England Journal of Medicine (2016)PMID: 27633186
Research Use Only

All findings above are sourced from peer-reviewed journals for educational reference. This product is for research purposes only — not for human consumption. Preclinical results may not translate to human outcomes.

Chemical Identity

Molecular FormulaC187H291N45O59
Molecular Weight4113.58 g/mol
CAS Number910463-68-2
ReferencePubChem ↗

How to Order

Three simple steps to access premium research peptides

1

Apply for an Account

Submit a quick application with your business details. Takes less than 2 minutes.

2

Get Approved

Our team reviews applications within 1–2 business days. You'll receive an email once approved.

3

Place Your Order

Browse the catalog, select quantities, and checkout. Volume pricing applies automatically.

Research Use Only

All products are for research and laboratory purposes only. Not intended for human or animal consumption. Only qualified professionals should handle these products.